{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:48:19Z","timestamp":1789073299554,"version":"build-2803163510"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Synopsis<\/jats:title>\n                    <jats:p>Tertiary lymphoid structures (TLSs) are linked to better outcomes in prostate cancer. Neoadjuvant hormone therapy enhances TLS formation, immune cell infiltration, and tumor response\u2014supporting the potential of combining hormone and immunotherapy for improved treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study investigates the characteristics and prognostic significance\u00a0of tertiary lymphoid structures (TLS) in prostate cancer (PCa), and explores\u00a0the\u00a0impact of neoadjuvant hormone therapy (NHT) on TLS formation and maturation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>TLS features and immune infiltration were assessed in PCa cohorts using H&amp;amp;E and multiplex immunohistochemistry (mIHC) for Ki67, panCK, CD21, CD4, CD8, and CD20. Public datasets compared TLS signatures between NHT-treated and NHT-na\u00efve patients, and between paired pre-\/post-NHT samples. An orthotopic immunocompetent PCa mouse model was generated using organoids and CRISPR-Cas9. Flow cytometry evaluated immune infiltration in bicalutamide-treated mice, and anti-PD1 was combined with degarelix\/bicalutamide in preclinical mouse model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>TLS were detected in 93% of NHT-na\u00efve PCa tissues, predominantly within tumors. Mature TLS, secondary follicle-like TLS (SFL-TLS), and higher intra-tumoral TLS density correlated with prolonged progression-free survival (PFS). NHT-treated patients exhibited elevated TLS maturity, density, and immune infiltration (CD4+, CD8+, CD20+, CD21+ cells). Matched biopsies confirmed NHT enhanced TLS detection, maturation, and intra-TLS CD8+ T cell infiltration. Transcriptomics revealed upregulated CD4, CD8, CD20, and FOXP3 post-NHT. In mice, androgen deprivation therapy (ADT) increased immune infiltration, and anti-PD1\/ADT combination improved tumor response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings demonstrate that TLS serve as a favorable prognostic biomarker in prostate cancer. NHT enhances TLS formation, maturation, and immune cell infiltration, suggesting a synergistic role for androgen deprivation in shaping the tumor immune microenvironment. The improved anti-tumor response with combined anti-PD1 and ADT highlights the potential of immunotherapy-endocrine therapy combinations as a promising treatment strategy for PCa.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1663396","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T07:12:53Z","timestamp":1762240373000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Characteristics of tertiary lymphoid structures in prostate cancer and the impact of neoadjuvant therapy on their formation and maturation"],"prefix":"10.3389","volume":"16","author":[{"given":"Shengzhuo","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangren","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianding","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 update on prostate cancer epidemiology and risk factors-A systematic review","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp2209151","article-title":"Screening for prostate cancer","volume":"388","author":"Pinsky","year":"2023","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer","volume":"398","author":"Sandhu","year":"2021","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100962","article-title":"Current therapy and drug resistance in metastatic castration-resistant prostate cancer","volume":"68","author":"Cai","year":"2023","journal-title":"Drug Resist Update"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01042-7","article-title":"Targeting signaling pathways in prostate cancer: mechanisms and clinical trials","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101199","article-title":"Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach","volume":"4","author":"Sridaran","year":"2023","journal-title":"Cell Rep Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217155","article-title":"Advances in and prospects of immunotherapy for prostate cancer","volume":"601","author":"Liu","year":"2024","journal-title":"Cancer Lett"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0060","article-title":"Androgen deprivation therapy drives a distinct immune phenotype in localized prostate cancer","volume":"30","author":"Dallos","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf9419","article-title":"Tertiary lymphoid structures in cancer","volume":"375","author":"Schumacher","year":"2022","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0029","article-title":"Distinct tertiary lymphoid structure associations and their prognostic relevance in HER2 positive and negative breast cancers","volume":"22","author":"Liu","year":"2017","journal-title":"Oncologist"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.693234","article-title":"Prognostic significance of gene signature of tertiary lymphoid structures in patients with lung adenocarcinoma","volume":"11","author":"Feng","year":"2021","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1987","article-title":"Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma","volume":"78","author":"Sili\u0146a","year":"2018","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2014.09.006","article-title":"Tertiary lymphoid structures in cancer and beyond","volume":"35","author":"Dieu-Nosjean","year":"2014","journal-title":"Trends Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1166497","article-title":"Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma","volume":"14","author":"Shang","year":"2023","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.02.001","article-title":"Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer","volume":"55","author":"Meylan","year":"2022","journal-title":"Immunity"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1342","article-title":"Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells","volume":"74","author":"Goc","year":"2014","journal-title":"Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01398-3","article-title":"An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer","volume":"27","author":"Voabil","year":"2021","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2929","article-title":"Early hepatic lesions display immature tertiary lymphoid structures and show elevated expression of immune inhibitory and immunosuppressive molecules","volume":"26","author":"Meylan","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.10.030","article-title":"Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma","volume":"76","author":"Ding","year":"2022","journal-title":"J Hepatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Saut\u00e8s-Fridman","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3836","article-title":"De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors","volume":"18","author":"Johansson-Percival","year":"2017","journal-title":"Nat Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00563","article-title":"A unique cellular and molecular microenvironment is present in tertiary lymphoid organs of patients with spontaneous prostate cancer regression","volume":"8","author":"Garc\u00eda-Hern\u00e1ndez","year":"2017","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24684","article-title":"Quantification and molecular correlates of tertiary lymphoid structures in primary prostate cancer","volume":"84","author":"Shahait","year":"2024","journal-title":"Prostate"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2025.06.003","article-title":"Spatial and maturity heterogeneity of tertiary lymphoid structures shapes immune microenvironment and progression in prostate cancer","volume":"5","author":"Wang","year":"2025","journal-title":"J Natl Cancer Center"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10100379","article-title":"Identification of the transcription factor relationships associated with androgen deprivation therapy response and metastatic progression in prostate cancer","volume":"10","author":"Sharma","year":"2018","journal-title":"Cancers"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2135-x","article-title":"A genomic and epigenomic atlas of prostate cancer in Asian populations","volume":"580","author":"Li","year":"2020","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"B M C Bioinf"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"P LoS Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2016.006","article-title":"Organoid culture systems for prostate epithelial and cancer tissue","volume":"11","author":"Drost","year":"2016","journal-title":"Nat Protoc"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.10.006","article-title":"Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer","volume":"41","author":"Hawley","year":"2023","journal-title":"Cancer Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-2742","article-title":"Ketogenic diet alters the epigenetic and immune landscape of prostate cancer to overcome resistance to immune checkpoint blockade therapy","volume":"84","author":"Murphy","year":"2024","journal-title":"Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.7150\/thno.73152","article-title":"Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy","volume":"12","author":"Ma","year":"2022","journal-title":"Theranostics"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04522-6","article-title":"Androgen receptor activity in T cells limits checkpoint blockade efficacy","volume":"606","author":"Guan","year":"2022","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.immuni.2022.05.012","article-title":"Androgen receptor-mediated CD8+ T cell stemness programs drive sex differences in antitumor immunity","volume":"55","author":"Yang","year":"2022","journal-title":"Immunity"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0559","article-title":"Androgen receptor inhibition increases MHC class I expression and improves immune response in prostate cancer","volume":"15","author":"Chesner","year":"2025","journal-title":"Cancer Discovery"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1663396\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T07:12:54Z","timestamp":1762240374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1663396\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2025.1663396"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1663396","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"article-number":"1663396"}}